Nascent Pharmaceuticals, Inc.'s Dry Eye Syndrome Clinical Trial Fully Enrolled 
10/19/2005 5:08:44 PM

BURLINGAME, Calif., June 7 /PRNewswire/ -- Nascent Pharmaceuticals, Inc. announced that it has completed enrollment of a 90-patient Phase IIb clinical trial of NP50301, Nascent's topical ophthalmic therapeutic eye drop for treating Dry Eye Syndrome (DES) in postmenopausal women. The clinical trial is a randomized, vehicle controlled, double masked study, with 30 patients in each of three arms, receiving either placebo, or one of two active doses. Data is being collected for both subjective symptoms and objective signs throughout the 14-week trial period.

"Completion of enrollment of the Phase IIb clinical trial is a significant milestone in the development of NP50301," said Gene Barnett, Ph.D., Vice President, Business Development, and a co-founder of Nascent Pharmaceuticals, Inc.

NP50301 is an estrogen ester compound believed to act by multiple mechanisms, including influencing the health of the cornea, the meibomian glands and the conjunctiva. It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S. The majority of sufferers of DES are postmenopausal women; and clinical research around the world has suggested the benefits of both topical and systemic estrogen therapy in the treatment of DES in this population.

"We are very pleased with the timely progress made to date and believe that Nascent is in an excellent position to capitalize on its robust pipeline of development-stage compounds," commented Douglas Beekman, Vice President of Advantage Capital Partners, Nascent's lead investor, and a Nascent Director.

About Nascent Pharmaceuticals, Inc.

Nascent Pharmaceuticals, Inc. is a privately held, no research/development-only specialty pharmaceutical company. The company's goal is to acquire commercially attractive, proprietary, and innovative pharmaceutical compounds and technologies; and as a result of the significant expertise of the management team, to develop the products through preclinical and early-stage clinical trials. Nascent has acquired compounds and technologies in the areas ophthalmology and oncology that are in various stages of development, including one in Phase IIb and one in Phase I. The company has offices in North Carolina and the San Francisco Bay Area. For more information, please visit our web site:

Nascent Pharmaceuticals, Inc.

CONTACT: Clive Reading, Chief Executive Officer, of NascentPharmaceuticals, Inc., +1-919-967-1998, or